Radioisotope Therapy - Cancer Science

What is Radioisotope Therapy?

Radioisotope therapy, also known as radionuclide therapy, is a type of targeted cancer treatment that utilizes radioactive substances to destroy cancer cells. These radioactive substances, called radioisotopes, can be administered orally, intravenously, or placed directly into the body near cancer cells.

How Does Radioisotope Therapy Work?

Once administered, radioisotopes emit radiation that targets cancerous cells. The radiation damages the DNA of these cells, which disrupts their ability to grow and divide, ultimately leading to cell death. Because the therapy is targeted, it minimizes damage to surrounding healthy tissues compared to conventional radiation therapy.

What Types of Cancer Can Be Treated with Radioisotope Therapy?

Radioisotope therapy is commonly used to treat various types of cancer, including:

Thyroid cancer: Iodine-131 is used to target thyroid cells.
Prostate cancer: Radium-223 is used to treat bone metastases.
Non-Hodgkin lymphoma: Yttrium-90 is used in certain radioimmunotherapies.
Neuroendocrine tumors: Lutetium-177 and Iodine-131 MIBG are used.

What are the Benefits of Radioisotope Therapy?

The primary benefits of radioisotope therapy include:

Targeted Treatment: It specifically targets cancer cells, minimizing damage to healthy tissues.
Reduced Side Effects: As the therapy is more focused, patients often experience fewer side effects compared to traditional radiation therapy.
Effectiveness: It can be highly effective in treating certain types of cancers that may not respond well to other treatments.

What are the Potential Side Effects?

While radioisotope therapy is generally well-tolerated, potential side effects can include:

Fatigue
Nausea or vomiting
Lowered blood cell counts

Relevant Publications

Optimal production and purification of n.c.a.Pr as a promising palliative agent for the treatment of metastatic bone pain.

Issue Release: 2024

Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging.

Issue Release: 2024

Actinium chelation and crystallization in a macromolecular scaffold.

Issue Release: 2024

Angiogenic biomarkers of response to treatment with peptide receptor radionuclide therapy in neuroendocrine tumours.

Issue Release: 2024

Radiosynovectomy in haemophilic synovitis and arthropathy of the knee: A scoping review.

Issue Release: 2024

Exploring Aqueous Coordination Chemistry of Highly Lewis Acidic Metals with Emerging Isotopes for Nuclear Medicine.

Issue Release: 2024

Radiolabeled florescent-magnetic graphene oxide nanosheets: probing the biodistribution of a potential PET-MRI hybrid imaging agent for detection of fibrosarcoma tumor.

Issue Release: 2024

Preclinical Evaluation and Pilot Clinical Study of F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2.

Issue Release: 2024

Clinical and dosimetric correlation in terms of treatment response, bladder and rectal toxicities in cervical cancer patients treated with cobalt 60 high dose rate brachytherapy.

Issue Release: 2024

Energy resolution improvement in simplified alpha spectroscopy for radionuclidic purity tests on 225Ac production floors.

Issue Release: 2024

Automated Radiosynthesis of [F]FluoFAPI and Its Dosimetry and Single Acute Dose Toxicological Evaluation.

Issue Release: 2024

Magnetically guided surgery after primary systemic therapy for breast cancer: implications for enhanced axillary mapping.

Issue Release: 2024

Tata Memorial Centre Evidence Based Use of Nuclear medicine diagnostic and treatment modalities in cancer.

Issue Release: 2024

[The lacrimal apparatus as an organ at risk during radionuclide therapy].

Issue Release: 2024

First Local Experience of Intra-Cavitary Yttrium-90 Citrate Colloid Irradiation via Ommaya Reservoir for Refractory Cystic Craniopharyngioma: a Case Report.

Issue Release: 2024

Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.

Issue Release: 2024

Thermoluminescence dosimetry (TLD) in a 3 T magnetic resonance imaging (MRI) environment: implications for personnel exposure monitoring.

Issue Release: 2024

Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [Tb]Tb-PSMA-I&T.

Issue Release: 2024

De-Escalating the Extent of Sentinel Lymph Node Biopsy in Patients With Ductal Carcinoma in Situ Undergoing Mastectomy.

Issue Release: 2024

Production, purification and formulation of nanoradiopharmaceutical with At: An emerging candidate for targeted alpha therapy.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics